Host endosomal entry / trafficking
MoreNasal & Oral Sprays / Rinses
MoreHost targets and pathways
MoreInflammatory and immune modulation
MoreOxidative stress and cytoprotection
MoreReplication inhibition (target unresolved)
MorePleiotropic modulation
MoreAttachment / entry inhibition
MoreNutrients and microbiome support
MoreIL-6 / IL-6R blockade
MorePhysical and extracorporeal interventions
MoreNatural products and extracts
MoreUnconfirmed antiviral rationale
MoreLifestyle, behaviors, and exposure prevention
MoreOther complication management
MoreHost pyrimidine synthesis
MoreDirect viral inactivation
MoreEndothelial / vascular protection
MoreDirect respiratory tract treatments
MoreOther antibodies, proteins, peptides, cells, and RNA therapies
MoreSecondary infection and coinfection management
More
227 patient dalcetrapib early treatment RCT: 134% higher mortality (p=1), 134% higher ventilation (p=1), 139% higher need for oxygen therapy (p=0.68), and 37% higher hospitalization (p=1).
RCT 227 COVID-19 outpatients with symptom onset within 5 days, showing no signficiant benefits with dalcetrapib treatment.
May 2021, NCT04676867, https://clinicaltrials.gov/study/NCT04676867, https://c19p.org/kallend